Abstract Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids
In studies, participants experienced meaningful reductions in body weight over several months, with results depending on dose level, duration, and individual response
Among its many possible pharmacologic properties, also anti-cancer effects have been reported
[PMID: 42485519] PubMed record related to this compound for laboratory literature review
The trial was sponsored by Novo Nordisk, the company that developed semaglutide
Avoid refined carbohydrates, white bread, sugary cereals, pastries, and anything with added sugars